PET/MRI Evaluation of Cardiac Amyloid

• Status: Completed
• Trial end date: 2018-08-28
• Target enrollment: 0
• Participant gender: All

Summary

Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University

Criteria

Inclusion Criteria:

• Patient is ≥ 18 years old at the time of the scan

• Patient with known or suspected cardiac amyloidosis.

• Patient is capable of complying with study procedures

Exclusion Criteria:

• Patient is pregnant or nursing

• Metallic implants (contraindicated for MRI)

• History of renal insufficiency (only for MRI contrast administration)